Pfizer recalls 1 million packets of US birth control pills

February 1, 2012 in Medications

US pharmaceutical giant Pfizer on Wednesday recalled one million packets of birth control pills over a packaging error that could put women at risk of unintended pregnancy.

The pills, about half of which were the brand name Lo/Ovral-28 and the other half were generic norgestrel and ethinyl estradiol tablets, may be improperly arranged so that inactive pills are taken at the wrong time in the monthly cycle.

Doctors described the recall as "very serious" and urged women who have been taking the pills to talk with their doctor and use back-up methods of protection.

A similar recall was issued in September by a different pharmaceutical company, Qualitest in Alabama, due to packaging errors that affected 1.4 million packets of birth control pills distributed in 2011.

Pfizer said its own investigation had "found that some blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence," the company said in a statement.

"As a result of this packaging error, the daily regimen for these oral contraceptives may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy."

The pills were manufactured and packaged by Pfizer in New York state and commercialized by Akrimax Rx Products under the Akrimax brand name in the United States.

Each packet is supposed to contain 21 active tablets and seven inactive pills.

"The cause of the inexact package counts has been identified and corrected," Pfizer spokeswoman Grace Ann Arnold told AFP.

She described the problem as a "mechanical and operator visual inspection systems failure on the packaging line."

Patients who have been taking the affected lot numbers, posted on the Pfizer and US Food and Drug Administration websites, should notify their physician, return the product to the pharmacy and begin using a back-up form of non-hormonal birth control right away.

"This is very, very serious," said Steven Goldstein, professor of obstetrics and gynecology at New York University Langone Medical Center. These pills "cannot be considered to be adequate contraception."

Goldstein added that the pills affected are not among the newer, low-dose pills that have risen in popularity in recent years, but may be commonly distributed by hospitals and low-cost outlets.

"It is a very old pill. It has been around for decades. There have been a number of newer, lower doses, better progestins, and it is not really marketed much anymore," he told AFP.

"A very small minority of people are probably taking this. However, anybody who is taking these packs may be at an unknown but too high of a risk for unintended pregnancy."

Gynecologist Jill Rabin at Long Island Jewish Medical Center in New York urged women who have been taking the affected pills to also get a pregnancy test.

"Sequence and content of active versus inactive pills is crucial in determining efficacy, including whether or not unwanted pregnancy will be actually prevented," she said.

"Ensure that you are not currently pregnant by taking a pregnancy test if you have any symptoms of pregnancy, such as missed periods, abnormal bleeding."

(c) 2012 AFP

not rated yet  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

Jesse_EngAmer
Feb 01, 2012

Rank: not rated yet
For a company, whose pill isn't considered cutting edge and is no longer a leading brand, to recall this many packages shows real concern for their customers. It's a good thing this got caught before any serious repercussions occurred. It's unfortunate we cannot say the same about the FDA who often put big pharma before the consumer. Just look at Vioxx: http://eng.am/mXtMkx
Rank not rated yet
Relevant PhysicsForums posts

More news stories

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Medications created 9 hours ago | popularity 4 / 5 (4) | comments 0

Global recommendations on child medicine

Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...

Medications created 10 hours ago | popularity not rated yet | comments 0

Analgesics prescribed more heavily to women than to men, study finds

Regardless of pain, social class or age, a woman is more likely to be prescribed pain-relieving drugs. A study published in Gaceta Sanitaria (Spanish health scientific journal) affirms that this phenomenon is inf ...

Medications created 18 hours ago | popularity not rated yet | comments 0

Breakup of physician, drug company relationship could improve health care, cut cost

A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...

Medications created May 20, 2013 | popularity 5 / 5 (1) | comments 0

FDA has safety concerns on Merck insomnia drug

Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

Medications created May 20, 2013 | popularity not rated yet | comments 0


If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Antidepressant reduces stress-induced heart condition

A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.

Drugs found to both prevent and treat Alzheimer's disease in mice

Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.